ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,350,000 shares, a growth of 27.7% from the November 30th total of 1,840,000 shares. Based on an average daily volume of 253,300 shares, the short-interest ratio is currently 9.3 days.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,231 shares of company stock valued at $2,434,286 in the last ninety days. Company insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the period. XTX Topco Ltd bought a new position in ANI Pharmaceuticals during the second quarter worth about $207,000. Profund Advisors LLC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth about $225,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $228,000. Finally, HighTower Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $222,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Down 0.4 %

ANIP stock opened at $54.21 on Tuesday. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The business’s 50 day moving average is $57.26 and its 200-day moving average is $59.47. The firm has a market cap of $1.14 billion, a P/E ratio of -98.56 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period last year, the firm posted $1.05 EPS. Equities analysts anticipate that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on ANIP shares. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.